Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012. The presentation will provide overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC).

The poster "Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial" A.J. Armstrong, M. Häggman, W.M. Stadler, J.R. Gingrich, V.J. Assikis, J. Polikoff, S.R. Denmeade, D. J. George, C. Andreou, W.R. Clark, P. Sieber, R. Agajanian, L. Belkoff, J-E. Damber, ö. Nordle, G. Forsberg, M. A. Carducci, R. Pili. will be presented on June 4 at 08:00 am CDT (3 :00 pm CET).

The abstract released today, based on 97 events, shows that overall survival after tasquinimod treatment is longer than previously reported in this patient population. Median time to death was 34.2 vs. 30.2 months (tasquinimod vs placebo). A preliminary subgroup analysis using the PCWG2 (Prostate Cancer Clinical Trials Working Group 2) defined criteria showed that median time to death in the bone-metastatic subgroup was 34.2 vs. 25.6 months (tasquinimod vs placebo). The impact of the cross-over design and the imbalance among groups in favor of placebo will be discussed in the presentation.

Source: Active Biotech